Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

NEW YORK, NY / ACCESSWIRE / April 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zoetis Inc. ("Zoetis Inc.") (NYSE:ZTS) concerning possible violations of federal securities laws. The Wall Street Journal released a shocking report on April 12, 2024, detailing the alarming number of adverse events associated with the animal osteoarthritis pain medications Librela and Solensia, manufactured by Zoetis.

Zoetis Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Zoetis Inc. (ZTS)

LOS ANGELES, CA / ACCESSWIRE / April 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm

Lost Money on Zoetis Inc. (ZTS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / April 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zoetis Inc. ("Zoetis Inc.") (NYSE:ZTS) concerning possible violations of federal securities laws. The Wall Street Journal released a shocking report on April 12, 2024, detailing the alarming number of adverse events associated with the animal osteoarthritis pain medications Librela and Solensia, manufactured by Zoetis.

Zoetis Inc. (ZTS) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

Zoetis Inc (NYSE:ZTS, ETR:ZOE) shares took a hit Friday after a Wall Street Journal report that suggested the company's arthritis shots may have sickened dogs and cats. The arthritis shots, Librela and Solensia, target osteoarthritis by focusing on nerve growth factor protein.

Zoetis shares drop amid concerns over arthritis shots' safety for pets

An article in The Wall Street Journal highlights the scrutiny over the company's arthritis treatments for pets.

Zoetis Stock Falls on Concerns Over Pet Arthritis Drugs. Company Says They're Safe.

Zoetis Inc.'s stock ZTS, -7.77% tumbled 7% Friday to lead S&P 500 decliners, after a Wall Street Journal report that the company's arthritis shots Librela and Solensia may have sickened pet cats and dogs. The two shots won Food and Drug Administration approval in 2022 and 2023 as the first antibody drugs for pets.

Zoetis's stock falls 7% to lead S&P 500 decliners after report its arthritis shots have sickened pets

Zoetis stock crumbled Friday after a report suggested the company's arthritis shots, Librela and Solensia, could have sickened dogs and cats.

Zoetis Stock Crumbles After Report Suggests Arthritis Shots Sickened Dogs, Cats

The latest trading day saw Zoetis (ZTS) settling at $165.69, representing a -0.1% change from its previous close.

Why Zoetis (ZTS) Dipped More Than Broader Market Today

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors. Mr. Hattersley brings global public company leadership and board experience, including as a current Chief Executive Officer and former Chief Financial Officer of Molson Coors, to the Zoetis Board. He will serve on the Board's Corporate Governance and Sustainability Committ.

Zoetis Appoints Gavin D.K. Hattersley to its Board of Directors

Coca-Cola European Partners plc

CRH PLC

Domino's Pizza

Elevance Health Inc

Global Payments

Mastercard

Monolithic Power Systems

MSCI

NIKE

Rollins

Ross Stores

Sirius XM Holdings Inc

UnitedHealth Group

Visa

The SPDR S&P 500 ETF Trust had a 3.27% return in March, outperforming Vanguard's Dividend Appreciation Index Fund ETF Shares. The top 15 dividend growth stocks for April 2024 offer an average dividend yield of 1.44% and appear to be about 24% undervalued based on dividend yield theory.

My Top 15 High Growth Dividend Stocks For April 2024

Lululemon Athletica

Southwest Airlines

Lululemon offered weaker-than-expected guidance in its fourth-quarter earnings report. Southwest cut its guidance in response to the crisis at Boeing.

Is It Time to Buy the S&P 500's 3 Worst-Performing Stocks of March?

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 2, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2024 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentation.

Zoetis to Host Webcast and Conference Call on First Quarter 2024 Financial Results

The European Commission on Tuesday said it had opened an antitrust investigation into possible breaches of EU competition rules by U.S. pet products maker Zoetis.

EU targets Zoetis in antitrust investigation over dog medicines

Booking Hlds

Estee Lauder

It is possible for retail investors to consistently beat the market by owning above-average blue chip dividend growth stocks. Hard work, research, and staying rational are key factors in outperforming the market. I highlight specific blue chip stocks, such as Booking Holdings, Zoetis, UnitedHealth Group, and Elevance Health, that have strong growth potential and attractive valuations.

You Don't Have To Take Excess Risk To Beat The Market

Zoetis Inc. has shown unique compounding results since spinning off from Pfizer, with double-digit EPS and dividend growth CAGRs since inception. The loneliness epidemic is driving demand for companion animals, and Zoetis is well positioned to benefit from the rise in pet ownership and pet-related spending. Zoetis has a strong position in the animal health market, with increased pricing power and limited competition, making it a best-in-class asset in the industry.

Zoetis: My Favorite Healthcare Stock Right Now

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Barclays Global Healthcare Conference on Thursday, March 14, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 8:30 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A rep.

Zoetis to Participate in the Barclays Global Healthcare Conference

Bank of America

Cigna

Microchip Technology

Old Dominion Freight Line

The SPDR S&P 500 ETF Trust had a 5.22% return in February, outperforming Vanguard's Dividend Appreciation Index Fund ETF Shares.

My Top 15 High Growth Dividend Stocks For March 2024

Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness

Zoetis is the world's largest producer of medicine and vaccinations for pets and livestock. It's also been incredibly profitable for its shareholders since its spinoff from Pfizer.

1 Magnificent S&P 500 Dividend Stock Down 23% to Buy Right Now

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2024 Animal Health Summit on Thursday, February 29, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 11:40 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-p.

Zoetis to Participate in the Bank of America Securities 2024 Animal Health Summit

Accenture Plc

Broadcom

Beating the S&P 500 is difficult due to skewed market returns favoring a few high-performing stocks.

5 Dividend Growth Stocks That Outperformed S&P 500 Over 5-Year Rolling Periods

Grifols, S.A.

Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?

GRFS or ZTS: Which Is the Better Value Stock Right Now?

Zoetis Inc. (ZTS) Q4 2023 Earnings Conference Call Transcript

Zoetis (ZTS) reports mixed fourth-quarter results, wherein earnings miss estimates while revenues beat the same.

News for Zoetis Stock (ZTS)